Renal cell carcinoma (RCC) accounts for 2-3% of all solid tumors. Expression of the receptor for the Vascular Endothelial Growth Factor (VEGF) is one of the most common features of RCC. Areas Covered: Lenvatinib is a novel multi-kinase inhibitor that has been studied in several solid tumors. It has shown promising results in the treatment of RCC, especially when combined with everolimus, In this review, we summarize the available data of lenvatinib for the treatment of advanced/metastatic renal cell carcinoma. Expert Opinion: Lenvatinib in combination with everolimus has provided encouraging results in both clinical and laboratory investigations showing that blocking angiogenesis and the mTOR signalling pathway could be a remarkable approach for treating RCC. As an additive to this type of approach it would be interesting in future clinical settings testing also the combination of lenvatinib and everolimus with immune-therapy.
Expert opinion on investigational drugs. 2018 May 02 [Epub ahead of print]
Giandomenico Roviello, Silvia Paola Corona, Giovanni Bozza, Michele Aieta, Daniele Generali, Maria Grazia Rodriquenz, Anna Maria Mileo, Marco Imperatori, Anna Ianza, Raffaele Conca, Navid Sobhani
a Division of Medical Oncology, Department of Onco-Hematology , IRCCS-CROB, Referral Cancer Center of Basilicata , via Padre Pio 1 85028 Rionero, Vulture ( PZ ), Italy., b Peter MacCallum Cancer Centre Moorabbin Campus , 865 Centre Road, Bentleigh East 3165 , Melbourne Vic , Australia., c Department of Medical , Surgery and Health Sciences, University of Trieste , Piazza Ospitale 1, 34129 Trieste , Italy.